Effect of age on breast cancer screening using tomosynthesis in combination with digital mammography
- 387 Downloads
To determine the effect of tomosynthesis imaging as a function of age for breast cancer screening.
Screening performance metrics from 13 institutions were examined for 12 months prior to introduction of tomosynthesis (period 1) and compared to those after introduction of tomosynthesis (period 2, range 3–22 months). Screening metrics for women ages 40–49, 50–59, 60–69, and 70+ , included rates per 1000 screens for recalls, biopsies, cancers, and invasive cancers detected.
Performance parameters were compared for women screened with digital mammography alone (n = 278,908) and digital mammography + tomosynthesis (n = 173,414). Addition of tomosynthesis to digital mammography produced significant reductions in recall rates for all age groups and significant increases in cancer detection rates for women 40–69. Largest recall rate reduction with tomosynthesis was for women 40–49, decreasing from 137 (95% CI 117–156) to 115 (95% CI 95–135); difference, −22 (95% CI −26 to −18; P < .001). Simultaneous increase in invasive cancer detection rate for women 40–49 from 1.6 (95% CI 1.2–1.9) to 2.7 (95% CI 2.2–3.1) with tomosynthesis (difference, 1.1; 95% CI 0.6–1.6; P < .001) was observed.
Addition of tomosynthesis to digital mammography increased invasive cancer detection rates for women 40–69 and decreased recall rates for all age groups with largest performance gains seen in women 40–49. The similar performance seen with tomosynthesis screening for women in their 40s compared to digital mammography for women in their 50s argues strongly for commencement of mammography screening at age 40 using tomosynthesis.
KeywordsBreast neoplasms Mammography Mass screening Cancer detection rate Biopsy
Elizabeth A. Rafferty, Stephen L. Rose, Melissa A. Durand, Debra Somers Copit, Sarah M. Friedewald, Donna M. Plecha, Ingrid L. Ott, Mary K. Hayes, Kara L. Carlson, Thomas M. Cink, Lora D. Barke, and Linda N. Greer received a research Grant from Hologic, Inc. Emily F. Conant received a research grant 5U54CA163316-03 from the National Cancer Institute.
Compliance with ethical standard
Conflict of interest
Dr. Rafferty, Dr. Rose, and Mr. Miller are consultants to Hologic, Inc. Drs. Friedewald, Plecha, Hayes, and Greer are consultants to Hologic, Inc. and on the Hologic, Inc. Scientific Advisory Board. Drs. Conant, Copit, and Carlson are on the Hologic, Inc. Scientific Advisory Board. Dr. Cink is Board Member Wellmark Blue Cross/Blue Shield for Iowa and South Dakota. Dr. Niklason is a former employee of Hologic, Inc., now retired.
- 11.Lång K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S (2016) Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the malmö breast tomosynthesis screening trial, a population-based study. Eur Radiol 26(1):184–190CrossRefPubMedGoogle Scholar
- 15.Gotzche PC, Jorgensen KJ (2013) Screening for breast cancer with mammography. Cochrane Database Syst Rev 6:CD001877Google Scholar